The spirometer market is valued at USD 950.0 million in 2021 and is poised to grow at a significant CAGR of 10.5% over 2022–2028. Patients with severe respiratory conditions currently put a heavy burden on healthcare systems around the world, and over the next ten years, this burden is expected to increase. The two primary factors driving the growth of the global market are the rise in the prevalence of chronic pulmonary diseases and the rising R&D expenditure on portable electronics. Spirometry is essential for the diagnosis, monitoring, and management of these patients. Results from spirometry tests are important to medical practitioners since they help with issue diagnosis. Spirometry is a crucial piece of technology in this regard because it helps determine the severity of the infection and prevents incorrect diagnoses. As a result, it is reasonable to anticipate that the market for spirometers will expand given the rising prevalence of these respiratory disorders. The efficiency of essential bodily organs and functions declines with age. Spirometry results may help in the diagnosis of a number of lung conditions. Spirometry is routinely used to evaluate how well asthma and COPD drugs are functioning, ensuring that patients are getting the most out of their treatment. The COVID-19 outbreak has increased the prevalence of numerous respiratory diseases. In the U.K., therapy for acute exacerbations of CPPD episodes increased over the first six weeks of the COVID-19 pandemic compared to 2019, according to a report published in ERJ Open Research in January 2021.
Recent Market Developments:
In April 2021, Along with its improved Spirotrac 6 software, Vitalograph unveiled the Pneumotrac spirometer of the next generation in the United States.
In September 2017, NuvoAir partnered with Novartis AG to expand the commercialization of NuvoAir’s spirometry technology to physicians worldwide